Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. (Q38397004)

From Wikidata

Jump to navigation Jump to search

scientific article published on 19 January 2016

Language	Label	Description	Also known as
English	Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.	scientific article published on 19 January 2016

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

0 references

Sebastian Grosicki

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Anders Österborg

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Miklós Udvardy

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Andrey Zaritskey

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Per-Ola Andersson

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Polina Kaplan

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Michael Steurer

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Anna Schuh

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Marco Montillo

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Iryna Kryachok

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Yaroslav Kulyaba

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Grygoriy Rekhtman

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Michele Gorczyca

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Siobhan Daly

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Chai-Ni Chang

17

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Steen Lisby

18

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Ira Gupta

19

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

publication date

19 January 2016

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Leukemia & Lymphoma

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

57

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

2037-2046

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26784000%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122783

21 January 2018

Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122783

21 January 2018

Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122783

21 January 2018

The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122783

21 January 2018

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122783

21 January 2018

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122783

21 January 2018

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122783

21 January 2018

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122783

21 January 2018

Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122783

21 January 2018

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122783

21 January 2018

Toxicity and response criteria of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122783

21 January 2018

Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122783

21 January 2018

Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122783

21 January 2018

Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients.

1 reference

https://api.crossref.org/works/10.3109%2F10428194.2015.1122783

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38397004&oldid=1509224669"